Clearance of hepatitis c virus improves insulin resistance during and after peginterferon and ribavirin therapy

Journal of Interferon and Cytokine Research

Volumn 35, Issue 12, 2015, Pages 981-989

  Chien, Cheng Hung ^a   Lin, Chih Lang ^a   Hu, Ching Chih ^a   Chang, Jia Jang ^a   Chien, Rong Nan ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; ALPHA INTERFERON; ANTIVIRUS AGENT;

ADULT; ANTIVIRAL THERAPY; ARTICLE; ASSESSMENT OF HUMANS; BODY WEIGHT; CHRONIC HEPATITIS C; FEMALE; GLUCOSE BLOOD LEVEL; HEPATITIS C VIRUS; HOMEOSTASIS MODEL ASSESSMENT; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE; VIRAL CLEARANCE; VIRUS LOAD; WEIGHT REDUCTION; AGED; BIOLOGICAL MODEL; COMBINATION DRUG THERAPY; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C; IMMUNOLOGY; MIDDLE AGED; RISK FACTOR; TREATMENT OUTCOME; VIROLOGY; YOUNG ADULT;

ADULT; AGED; ANTIVIRAL AGENTS; BODY WEIGHT; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; INSULIN RESISTANCE; INTERFERON-ALPHA; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; RIBAVIRIN; RISK FACTORS; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84951731059     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.2014.0200     Document Type: Article

References (40)

1. Arase Y, Suzuki F, Suzuki Y, Akuta N, Kobayashi M, Kawamura Y, Yatsuji H, Sezaki H, Hosaka T, Hirakawa M, Ikeda K, Kumada H. 2009. Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology 49(3):739-744.
2. Chuang WL, Yu ML. 2013. Host factors determining the efficacy of hepatitis C treatment. J Gastroenterol 48(1):22-30.
3. Chung RT, Poordad FF, Hassanein T, Zhou X, Lentz E, Prabhakar A, Di Bisceglie AM. 2010. Association of host pharmacodynamic effects with virologic response to pegylated interferon alfa-2a/ribavirin in chronic hepatitis C. Hepatology 52(6):1906-1914.
4. Conjeevaram HS, Wahed AS, Afdhal N, Howell CD, Everhart JE, Hoofnagle JH, Virahep CSG. 2011. Changes in insulin sensitivity and body weight during and after peginterferon and ribavirin therapy for hepatitis C. Gastroenterology 140(2):469-477.
5. Dai C-Y, Huang J-F, Hsieh M-Y, Hou N-J, Lin Z-Y, Chen S-C, Hsieh M-Y, Wang L-Y, Chang W-Y, Chuang W-L, Yu M-L. 2009. Insulin resistance predicts response to peginterferonalpha/ribavirin combination therapy in chronic hepatitis C patients. J Hepatol 50(4):712-718.
6. Daniel AL, Houlihan JL, Blum JS, Walsh JP. 2009. Type B insulin resistance developing during interferon-alpha therapy. Endocr Pract 15(2):153-157.
7. Delgado-Borrego A, Jordan SH, Negre B, Healey D, Lin W, Kamegaya Y, Christofi M, Ludwig DA, Lok AS, Chung RT, Halt CTG. 2010. Reduction of insulin resistance with effective clearance of hepatitis C infection: results from the HALT-C trial. Clin Gastroenterol Hepatol 8(5):458-462.
8. Deltenre P, Louvet A, Lemoine M, Mourad A, Fartoux L, Moreno C, Henrion J, Mathurin P, Serfaty L. 2011. Impact of insulin resistance on sustained response in HCV patients treated with pegylated interferon and ribavirin: a metaanalysis. J Hepatol 55(6):1187-1194.
9. Eslam M, Aparcero R, Kawaguchi T, Del Campo JA, Sata M, Khattab MA, Romero-Gomez M. 2011a. Meta-analysis: insulin resistance and sustained virological response in hepatitis C. Aliment Pharmacol Ther 34(3):297-305.
10. Eslam M, Khattab MA, Harrison SA. 2011b. Insulin resistance and hepatitis C: an evolving story. Gut 60(8):1139-1151.
11. Fabris P, Floreani A, Tositti G, Vergani D, De Lalla F, Betterle C. 2003. Type 1 diabetes mellitus in patients with chronic hepatitis C before and after interferon therapy. Aliment Pharmacol Ther 18(6):549-558.
12. Fried MW. 2002. Side effects of therapy of hepatitis C and their management. Hepatology 36(5 Suppl 1):S237-S244.
13. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. 2009. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461(7262):399-401.
14. Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. 2009. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 49(4):1335-1374.
15. Hsu YC, Lin JT, Ho HJ, Kao YH, Huang YT, Hsiao NW, Wu MS, Liu YY, Wu CY. 2014. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. Hepatology 59(4): 1293-1302.
16. Huang JF, Dai CY, Yu ML, Huang CF, Huang CI, Yeh ML, Yang JF, Hou NJ, Hsiao PJ, Lin ZY, Chen SC, Shin SJ, Chuang WL. 2011. Pegylated interferon plus ribavirin therapy improves pancreatic beta-cell function in chronic hepatitis C patients. Liver Int 31(8):1155-1162.
17. Huang JF, Yu ML, Huang CF, Juo SH, Dai CY, Hsieh MY, Hou NJ, Yeh ML, Hsieh MH, Yang JF, Lin ZY, Chen SC, Shin SJ, Chuang WL. 2012. The outcomes of glucose abnormalities in pre-diabetic chronic hepatitis C patients receiving peginterferon plus ribavirin therapy. Liver Int 32(6):962-969.
18. Hui JM, Sud A, Farrell GC, Bandara P, Byth K, Kench JG, McCaughan GW, George J. 2003. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. Gastroenterology 125(6):1695-1704.
19. Hung CH, Lee CM, Lu SN. 2011. Hepatitis C virus-associated insulin resistance: pathogenic mechanisms and clinical implications. Expert Rev Anti Infect Ther 9(5):525-533.
20. Hung CH, Lu SN, Wang JH, Lee CM, Chen TM, Tung HD, Chen CH, Huang WS, Changchien CS. 2003. Correlation between ultrasonographic and pathologic diagnoses of hepatitis B and C virus-related cirrhosis. J Gastroenterol 38(2):153-157.
21. Imano E, Kanda T, Ishigami Y, Kubota M, Ikeda M, Matsuhisa M, Kawamori R, Yamasaki Y. 1998. Interferon induces insulin resistance in patients with chronic active hepatitis C. J Hepatol 28(2):189-193.
22. Kawaguchi T, Ide T, Taniguchi E, Hirano E, Itou M, Sumie S, Nagao Y, Yanagimoto C, Hanada S, Koga H, Sata M. 2007. Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2. Am J Gastroenterol 102(3):570-576.
23. Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, Jeon WK, Kim BI. 2009. Clearance of HCV by combination therapy of pegylated interferon alpha-2a and ribavirin improves insulin resistance. Gut Liver 3(2):108-115.
24. Lin D, Sheen I, Chiu C, Lin S, Kuo Y, Chien R. 1993. Clinical significance of ultrasonographic fatty liver in asymptomatics: analysis of 1040 check-up subjects. JMed ultrasound 1:165-171.
25. Lin ZH, Xin YN, Dong QJ, Wang Q, Jiang XJ, Zhan SH, Sun Y, Xuan SY. 2011. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology 53(3):726-736.
26. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. 1985. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28(7):412-419.
27. Moucari R, Asselah T, Cazals-Hatem D, Voitot H, Boyer N, Ripault MP, Sobesky R, Martinot-Peignoux M, Maylin S, Nicolas-Chanoine MH, Paradis V, Vidaud M, Valla D, Bedossa P, Marcellin P. 2008. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 134(2):416-423.
28. Moucari R, Forestier N, Larrey D, Guyader D, Couzigou P, Benhamou Y, Voitot H, Vidaud M, Seiwert S, Bradford B, Zeuzem S, Marcellin P. 2010. Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C. Gut 59(12):1694-1698.
29. Nakamura K, Kawasaki E, Imagawa A, Awata T, Ikegami H, Uchigata Y, Kobayashi T, Shimada A, Nakanishi K, Makino H, Maruyama T, Hanafusa T; Research Committee on Type 1 Diabetes of the Japan Diabetes Society. 2011. Type 1 diabetes and interferon therapy: a nationwide survey in Japan. Diabetes Care 34(9):2084-2089.
30. Pazienza V, Clement S, Pugnale P, Conzelman S, Foti M, Mangia A, Negro F. 2007. The hepatitisCvirus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms. Hepatology 45(5):1164-1171.
31. Romero-Gomez M, Del Mar Viloria M, Andrade RJ, Salmeron J, Diago M, Fernandez-Rodriguez CM, Corpas R, Cruz M, Grande L, Vazquez L, Munoz-De-Rueda P, Lopez-Serrano P, Gila A, Gutierrez ML, Perez C, Ruiz-Extremera A, Suarez E, Castillo J. 2005. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 128(3):636-641.
32. Romero-Gomez M, Fernandez-Rodriguez CM, Andrade RJ, Diago M, Alonso S, Planas R, Sola R, Pons JA, Salmeron J, Barcena R, Perez R, Carmona I, Duran S. 2008. Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C. J Hepatol 48(5):721-727.
33. Schreuder TC, Gelderblom HC, Weegink CJ, Hamann D, Reesink HW, Devries JH, Hoekstra JB, Jansen PL. 2008. High incidence of type 1 diabetes mellitus during or shortly after treatment with pegylated interferon alpha for chronic hepatitis C virus infection. Liver Int 28(1):39-46.
34. Serfaty L, Forns X, Goeser T, Ferenci P, Nevens F, Carosi G, Drenth JP, Lonjon-Domanec I, DeMasi R, Picchio G, Beumont M, Marcellin P. 2012. Insulin resistance and response to telaprevir plus peginterferon alpha and ribavirin in treatmentnaive patients infected with HCV genotype 1. Gut 61(10): 1473-1480.
35. Seyam MS, Freshwater DA, O'Donnell K, Mutimer DJ. 2005. Weight loss during pegylated interferon and ribavirin treatment of chronic hepatitis C. J Viral Hepat 12(5):531-535.
36. Tai TY, Lu JY, Chen CL, Lai MY, Chen PJ, Kao JH, Lee CZ, Lee HS, Chuang LM, Jeng YM. 2003. Interferon-alpha reduces insulin resistance and beta-cell secretion in responders among patients with chronic hepatitis B and C. J Endocrinol 178(3):457-465.
37. Thompson AJ, Patel K, Chuang WL, Lawitz EJ, Rodriguez-Torres M, Rustgi VK, Flisiak R, Pianko S, Diago M, Arora S, Foster GR, Torbenson M, Benhamou Y, Nelson DR, Sulkowski MS, Zeuzem S, Pulkstenis E, Subramanian GM, McHutchison JG, Achieve, Teams A-S. 2012. Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3. Gut 61(1):128-134.
38. Yoneda M, Saito S, Ikeda T, Fujita K, Mawatari H, Kirikoshi H, Inamori M, Nozaki Y, Akiyama T, Takahashi H, Abe Y, Kubota K, Iwasaki T, Terauchi Y, Togo S, Nakajima A. 2007. Hepatitis C virus directly associates with insulin resistance independent of the visceral fat area in nonobese and nondiabetic patients. J Viral Hepat 14(9):600-607.
39. Younossi Z, Negro F, Serfaty L, Pol S, Diago M, Zeuzem S, Andreone P, Lawitz EJ, Roberts S, Focaccia R, Foster GR, Horban A, Lonjon-Domanec I, Coate B, DeMasi R, Picchio G, Witek J. 2013. Homeostasis model assessment of insulin resistance does not seemto predict response to telaprevir in chronic hepatitisCin the REALIZE trial. Hepatology 58(6):1897-1906.
40. Zornitzki T, Malnick S, Lysyy L, Knobler H. 2015. Interferon therapy in hepatitis C leading to chronic type 1 diabetes. World J Gastroenterol 21(1):233-239.